353 related articles for article (PubMed ID: 29359667)
1. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
2.
Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M
Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312
[TBL] [Abstract][Full Text] [Related]
3. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
4. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.
Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X
Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039
[TBL] [Abstract][Full Text] [Related]
6. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide.
Sahu BP; Das MK
Acta Pol Pharm; 2014; 71(1):129-37. PubMed ID: 24779201
[TBL] [Abstract][Full Text] [Related]
7. Quality by design approach to understand the process of nanosuspension preparation.
Verma S; Lan Y; Gokhale R; Burgess DJ
Int J Pharm; 2009 Jul; 377(1-2):185-98. PubMed ID: 19446617
[TBL] [Abstract][Full Text] [Related]
8. Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.
Alshweiat A; Katona G; Csóka I; Ambrus R
Eur J Pharm Sci; 2018 Sep; 122():94-104. PubMed ID: 29908301
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
10. Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach.
Kuk DH; Ha ES; Ha DH; Sim WY; Lee SK; Jeong JS; Kim JS; Baek IH; Park H; Choi DH; Yoo JW; Jeong SH; Hwang SJ; Kim MS
Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31861173
[TBL] [Abstract][Full Text] [Related]
11. [Preparation and characterization of icariin nanosuspension and lyophilized powder].
Hui-Rong XI; Hui-Ping MA; Ke-Ming C; Xiao-Shuan L
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):4902-4908. PubMed ID: 33350263
[TBL] [Abstract][Full Text] [Related]
12. Development of Atovaquone Nanosuspension: Quality by Design Approach.
Kakade P; Gite S; Patravale V
Curr Drug Deliv; 2020; 17(2):112-125. PubMed ID: 31880260
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.
Jakubowska E; Milanowski B; Lulek J
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830298
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment.
Shekhawat P; Pokharkar V
Int J Pharm; 2019 Aug; 567():118415. PubMed ID: 31175989
[TBL] [Abstract][Full Text] [Related]
15. Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.
Rao MR; Bajaj A
Drug Res (Stuttg); 2014 Dec; 64(12):663-7. PubMed ID: 24549965
[TBL] [Abstract][Full Text] [Related]
16. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation.
Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B
Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130
[TBL] [Abstract][Full Text] [Related]
18. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability.
Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J
Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
Parmar K; Shah J
Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
